TScan Therapeutics, Inc. (TCRX): restructuring charge — TScan Therapeutics restructures, cuts 30% of workforce, pauses solid tumor trial, extends cash runway to H2 2027

TScan Therapeutics, Inc.

FDA agrees to pivotal study design for TSC-101 in AML/MDS; trial to start Q2 2026.
Workforce reduced by ~30% (66 roles); expects $2.3M severance charge in Q4 2025.
Strategic prioritization yields ~$45M annual cost savings in 2026-27; cash runway extended to H2 2027.
Pauses further enrollment in solid tumor Phase 1 PLEXI-T trial; to present initial data Q1 2026.
First two patients dosed with multiplex TCR-T in solid tumors; shifting preclinical focus to in vivo engineering.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

TScan Therapeutics, Inc. announced a restructuring with charges of up to approximately $2.3 million affecting the Company (approximately 30% of the Company’s workforce, or 66 roles).

Type: restructuring
Charge: up to approximately $2.3 million
Affected area: the Company
Headcount: approximately 30% of the Company’s workforce, or 66 roles

Exact text from the filing

On November 3, 2025, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the clinical development of its heme program, pause further enrollment in its solid tumor Phase 1 trial, and focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity. Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 30% of the Company’s workforce, or 66 roles. The Company expects to record a one-time charge of up to approximately $2.3 million during the three months ended December 31, 2025, for severance-related benefits and other costs.

View on SEC.gov

Browse all restructurings & charges →

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-261612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.